Description
ACE-031 is a recombinant fusion protein compound consisting of the extracellular domain of the Activin Type IIB receptor (ActRIIB) and the Fc region of human IgG1. The substance functions as a decoy receptor binding myostatin and related ligands (Activin A, GDF-11) and thereby preventing their signal action at the actual ActRIIB receptor.
Per study reports ACE-031 blocks the myostatin pathway - myostatin is the central negative regulator of muscle growth. Studies in animal models with myostatin knockout (e.g., Belgian Blue cattle, Schwarzenegger mice) show dramatic muscle hypertrophy. ACE-031 mimics this knockout effect pharmacologically.
Acceleron Pharma developed ACE-031 for Duchenne muscular dystrophy (DMD) research in clinical Phase II. Studies showed significant muscle hypertrophy but were stopped due to severe side effects (nosebleeds, telangiectasias).
In the recreational community ACE-031 is a young and very potent anabolic compound, but cardiac and vascular safety data isn’t complete. The substance blocks not only myostatin but also related ligands, explaining off-target effects.
Pharmacokinetically subcutaneous or intravenous. Half-life long due to Fc portion (about 10-15 days).
You can order ACE-031 as lyophilized peptide in 10-pack at 5mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
ACE-031 is a young and very potent anabolic compound whose safety data is less complete compared to the classical healing peptides. As an Fc fusion protein with a long half-life, the action persists for roughly two weeks.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site with subcutaneous use.
- Vascular effects: nosebleeds and telangiectasias (dilated small blood vessels) were documented in the clinical Phase II studies - the reason the studies were stopped. This is the central observation point of this compound.
- Off-target binding: ACE-031 blocks not only myostatin but also related ligands such as Activin A and GDF-11, which explains the vascular off-target effects.
- Long half-life: due to the Fc portion, the substance remains active for roughly 10-15 days, so a reaction that has occurred subsides correspondingly slowly.
- No long-term data: cardiac and vascular safety data is not complete. Robust long-term human studies do not exist.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers - Muscle & Nerve 2012, Attie et al: pivotal Phase 1 study of the Acceleron program.
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial - Muscle & Nerve 2016, Campbell et al: published Phase 2 data in DMD including safety profile.
- Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child - NEJM 2004, Schuelke et al: classic human myostatin loss-of-function observation.
- Regulation of myostatin activity and muscle growth - PNAS 2001, Lee & McPherron: mechanism study on myostatin regulation and muscle hypertrophy.
